

Renalytix plc
("Renalytix" or the "Company")

Update Regarding Forward Guidance

LONDON and NEW YORK, 24 September 2025 - Renalytix plc (LSE: RENX) a precision medicine company with *kidneyintelX.dkd*, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, provides a further comment regarding revenue guidance following the Company's announcement dated 23 September 2025.

The Company would like to clarify that the forward revenue guidance provided does not include full consideration of the implications of its recently [announced collaboration with Tempus AI](#), Inc. ("Tempus"). As it is too early to predict revenue contributions from this new relationship with Tempus, the Company expects to provide shareholders with updates in due course.

For further information, please contact:

Renalytix Plc
James McCullough, CEO

www.renalytix.com
Via Walbrook PR

SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)

Tel: 0203 470 0470

Jeff Keating / David Hignell (Corporate Finance)
Vadim Alexandre (Corporate Broking)

Oberon Capital (Sole Bookrunner and Joint Broker)
Mike Seabrook / Nick Lovering / Aimee McCusker

Tel: 020 3179 5300

Walbrook PR Limited
Paul McManus / Alice Woodings

Tel: 020 7933 8780 or renalytix@walbrookpr.com
Mob: 07980 541 893 / 07407 804 654

*The person responsible for making this Announcement on behalf of the Company is
James McCullagh, Chief Executive Officer.*

About Renalytix (www.renalytix.com)

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled *in vitro* diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for *kidneyintelX.dkd* which is now offered commercially in the United States.

Unrecognized and uncontrolled kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom's medical system, affecting over 14 million and 8 million people, respectively. After five years of development and clinical validation, *kidneyintelX.dkd* is the only FDA-approved and Medicare reimbursed prognostic tool capable of understanding a patient's risk with kidney disease early where treatment has maximal effect. *kidneyintelX.dkd* is now being deployed across large physician group practices and health systems in select regions of the United States.

The over 15,000 patients that have been tested by *kidneyintelX.dkd* have produced a substantial body of real-world performance data. In patient populations where *kidneyintelX.dkd* has been deployed, a demonstrated and significant increase in diagnosis, prognosis, and treatment rates have been recorded. *kidneyintelX.dkd* now has full reimbursement established by Medicare, the largest insurance payer in the United States, at 950 per reportable result. *kidneyintelX.dkd* is also recommended for use in the international chronic kidney disease clinical guidelines (KDIGO).

KidneyIntelX is based on technology developed by Mount Sinai faculty and licensed to Renalytix AI, Inc. Mount Sinai faculty members are co-founders and equity owners in the Company. In addition, the Icahn School of Medicine at Mount Sinai has equity ownership in Renalytix. For information about the *kidneyintelX.dkd* test, visit kidneyintelx.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

UPDDZGZLZDLGKZM